Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-24 @ 9:22 PM
Ignite Modification Date:
2025-12-25 @ 7:09 PM
NCT ID:
NCT03456804
Group ID:
EG000
Title:
Treatment ESK981
Description:
Patients receive pan-VEGFR/TIE2 (Vascular Endothelial Growth Factor Receptor/angopoeitin receptor2) tyrosine kinase inhibitor CEP-11981 PO QD for 5 days (Monday-Friday). Treatment repeats for up to 8 weeks in the absence of disease progression or unacceptable toxicity. If treatment is successful after 8 weeks, patients may receive up to 6 months of pan-VEGFR/TIE2 tyrosine kinase inhibitor CEP-11981.
ESK981: Treatment with ESK981 for patients with metastatic castrate resistant prostate cancer
Deaths Number Affected:
10
Deaths Number At Risk:
None
Serious Number Affected:
5
Serious Number At Risk:
13
Other Number Affected:
13
Other Number At Risk:
13
Study:
NCT03456804
Results Section:
NCT03456804
Adverse Events Module:
NCT03456804